A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, February 2010

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (72nd percentile)
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

So far, Altmetric has seen 6 patents that reference this research output.

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity, including 2 additional patents.